Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 65.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,612 shares of the medical device company's stock after buying an additional 20,467 shares during the period. Quantinno Capital Management LP owned 0.08% of Tandem Diabetes Care worth $1,859,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of TNDM. Arizona State Retirement System increased its position in shares of Tandem Diabetes Care by 1.9% during the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock worth $683,000 after purchasing an additional 362 shares in the last quarter. Bank of Montreal Can increased its position in shares of Tandem Diabetes Care by 4.3% during the fourth quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock worth $360,000 after purchasing an additional 409 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Tandem Diabetes Care by 8.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company's stock worth $247,000 after purchasing an additional 525 shares in the last quarter. Assetmark Inc. increased its position in shares of Tandem Diabetes Care by 77.5% during the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after purchasing an additional 541 shares in the last quarter.

Tandem Diabetes Care Stock Performance

TNDM traded up $0.08 during midday trading on Friday, hitting $20.72. 945,052 shares of the company were exchanged, compared to its average volume of 1,487,297. The company's 50 day simple moving average is $19.40 and its 200 day simple moving average is $27.46. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -10.74 and a beta of 1.47. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. During the same period in the previous year, the company earned ($0.65) earnings per share. The company's revenue was up 22.3% compared to the same quarter last year. As a group, sell-side analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.90% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on TNDM shares. Mizuho started coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target on the stock. Robert W. Baird cut their target price on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research report on Thursday, May 1st. Citigroup upped their target price on Tandem Diabetes Care from $20.00 to $24.00 and gave the company a "neutral" rating in a research report on Thursday. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Finally, Morgan Stanley downgraded Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.47.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.